-
Je něco špatně v tomto záznamu ?
Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents
Melichar B, Dvorák J, Hyspler R, Zadák Z.
Jazyk angličtina Země Švýcarsko
Grantová podpora
NR8156
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
NLK
Karger Journals
od 1998-01-01 do 2009
ProQuest Central
od 1998-01-01 do 2015-11-30
Health & Medicine (ProQuest)
od 1998-01-01 do 2015-11-30
PubMed
16224185
DOI
10.1159/000088957
Knihovny.cz E-zdroje
- MeSH
- financování organizované MeSH
- lidé MeSH
- mukozitida diagnóza chemicky indukované MeSH
- nádory farmakoterapie komplikace MeSH
- nemoci střev diagnóza chemicky indukované MeSH
- permeabilita MeSH
- protinádorové látky škodlivé účinky MeSH
- střevní sliznice imunologie metabolismus účinky léků MeSH
- Check Tag
- lidé MeSH
The diagnosis and assessment of the severity of intestinal mucosal damage in cancer patients treated with cytotoxic drugs still rely on anamnestic data. There is cumulative evidence that measurement of intestinal permeability may represent a sensitive indicator of intestinal damage by cytotoxic agents. The intestinal permeability testing is based on differential permeability of tight junctions along the crypt-villus axis to nonmetabolized sugars. Cytotoxic drugs induce flattening of villi, leading to increased exposure of luminal contents to crypts and increased disaccharide absorption. An increased disaccharide/monosaccharide ratio and decreased xylose absorption have been described in patients treated with different cytotoxic drugs across a spectrum of malignant tumors that correlated with clinical manifestations, and were used to monitor the effect of therapeutic interventions. Copyright 2005 S. Karger AG, Basel.
Citace poskytuje Crossref.org
- 000
- 02596naa 2200361 a 4500
- 001
- bmc07507249
- 003
- CZ-PrNML
- 005
- 20131008140559.0
- 008
- 080801s2005 sz e eng||
- 009
- AR
- 024 __
- $a 10.1159/000088957 $2 doi
- 035 __
- $a (PubMed)16224185
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Melichar, Bohuslav, $d 1965- $7 skuk0000853
- 245 10
- $a Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents / $c Melichar B, Dvorák J, Hyspler R, Zadák Z.
- 314 __
- $a Department of Oncology and Radiotherapy, Charles University Medical School Teaching Hospital, Hradec Králové, Czech Republic. melichar@fnhk.cz
- 520 9_
- $a The diagnosis and assessment of the severity of intestinal mucosal damage in cancer patients treated with cytotoxic drugs still rely on anamnestic data. There is cumulative evidence that measurement of intestinal permeability may represent a sensitive indicator of intestinal damage by cytotoxic agents. The intestinal permeability testing is based on differential permeability of tight junctions along the crypt-villus axis to nonmetabolized sugars. Cytotoxic drugs induce flattening of villi, leading to increased exposure of luminal contents to crypts and increased disaccharide absorption. An increased disaccharide/monosaccharide ratio and decreased xylose absorption have been described in patients treated with different cytotoxic drugs across a spectrum of malignant tumors that correlated with clinical manifestations, and were used to monitor the effect of therapeutic interventions. Copyright 2005 S. Karger AG, Basel.
- 650 _2
- $a protinádorové látky $x škodlivé účinky $7 D000970
- 650 _2
- $a nemoci střev $x diagnóza $x chemicky indukované $7 D007410
- 650 _2
- $a střevní sliznice $x imunologie $x metabolismus $x účinky léků $7 D007413
- 650 _2
- $a nádory $x farmakoterapie $x komplikace $7 D009369
- 650 _2
- $a mukozitida $x diagnóza $x chemicky indukované $7 D052016
- 650 _2
- $a permeabilita $7 D010539
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Dvořák, Josef, $d 1966- $7 xx0072583
- 700 1_
- $a Hyšpler, Radomír, $d 1972- $7 nlk20040155091
- 700 1_
- $a Zadák, Zdeněk, $d 1937- $7 nlk19990074064
- 773 0_
- $w MED00002125 $t Chemotherapy $g Roč. 51, č. 6 (2005), s. 336-338 $x 0009-3157
- 910 __
- $a ABA008 $b x $y 9 $z 0
- 990 __
- $a 20080721085927 $b ABA008
- 991 __
- $a 20131008141121 $b ABA008
- 999 __
- $a ok $b bmc $g 622855 $s 475288
- BAS __
- $a 3
- BMC __
- $a 2005 $b 51 $c 6 $d 336-338 $i 0009-3157 $m Chemotherapy $x MED00002125
- GRA __
- $a NR8156 $p MZ0
- LZP __
- $a 2008-Doreen
